Ribonexus
Paris · Founded 2021
About Ribonexus
Ribonexus is a biotech specializing in the development of new therapies to combat cancer disease. Ribonexus, whose research and development programs are focused on the treatment of melanoma, is developing a pipeline of molecules that target the eukaryotic translation Initiation Factor-4A. (eIF4A). This target is active in a wide range of solid and hematologic cancers, including melanoma, and is linked to resistance to many current treatments. Ribonexus's goal is to deliver drugs that restore sensitivity to current targeted therapies in cancer patients who have become resistant to them.
Company Facts
- Founded: 2021
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $6.8M
- Funding stage: Seed
- Last round: Debt Financing (Apr 2022)
- Website: https://ribonexus-project.com
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Canonical: https://fsome.com/organization/ribonexus-25659 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.